Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment